Thymalfasin Plus Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Cancer
Xu H, Li F, Li B, et al.
Summary
Neoadjuvant immunochemotherapy combined with thymalfasin showed promising results in locally advanced gastric cancer, enhancing immune response in the tumor microenvironment.
Clinical Significance
Provides clinical evidence for thymalfasin as an immune-enhancing adjunct in cancer treatment.
Study Design
- Patients: Locally advanced gastric cancer
- Intervention: Neoadjuvant immunochemotherapy + thymalfasin
- Type: Prospective clinical trial
Key Findings
- Enhanced immune cell infiltration in tumor microenvironment
- Improved pathological response rates
- Thymalfasin boosted anti-tumor immunity when combined with checkpoint inhibitors
- Manageable safety profile
Clinical Relevance
Thymalfasin's immune-modulating properties make it a promising adjunct to immunotherapy in oncology settings.
Source
Relatert forskning
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells in Liver Cancer via PI3K/AKT Suppression
The combination of IL-15 and thymosin α1 reduced senescent CD8+ T cells in hepatocellular carcinoma …
Thymosin α1-Induced IL-15/RA Secretion Restrains HIV Latency In Vitro
Thymosin α1 induced dendritic cells to secrete IL-15/retinoic acid complex, which helped restrain HI…
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant ant…
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, …